Report of Foreign Issuer (6-k)
December 31 2019 - 2:13PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
6-K
Report
of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16
Under
the Securities Exchange Act of 1934
For
the Month of December, 2019
Commission
File Number: 001-37353
BIONDVAX
PHARMACEUTICALS LTD.
(Translation
of registrant’s name into English)
Jerusalem
BioPark, 2nd Floor
Hadassah
Ein Kerem Campus
Jeusalem,
Israel
(Address
of principal executive office)
Indicate
by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):
____
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):
____
BiondVax
Pharmaceuticals Ltd. (hereinafter, the “Company”) announces that it will hold an Annual General Meeting of Shareholders
on February 11, 2020, at 4:00 p.m. Israel time, at the offices of Gross, Kleinhendler, Hodak, Halevy, Greenberg, Shenhav &
Co., One Azrieli Center, Tel Aviv 6701101, Israel.
The
Company hereby furnishes as Exhibit 99.1 to this
Form 6-K a Notice with respect to the Company’s Annual General Meeting
of Shareholders to be held on February 11, 2020.
Exhibit
Index
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.
|
BiondVax Pharmaceuticals Ltd.
|
|
|
|
Date: December 31, 2019
|
By:
|
/s/
Ron Babecoff
|
|
|
Ron Babecoff
|
|
|
Chief Executive Officer
|
2
BiondVax Pharmaceuticals (NASDAQ:BVXV)
Historical Stock Chart
From Mar 2024 to Apr 2024
BiondVax Pharmaceuticals (NASDAQ:BVXV)
Historical Stock Chart
From Apr 2023 to Apr 2024